Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03206463 · ClinicalTrials.gov registry record · Phase 1
Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder
A Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03206463 is a Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 2 participants.
The verdict
NCT03206463, a Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The overarching goal of this study is to characterize the acute cognitive and psychophysiological effects of the main psychoactive constituent of cannabis, 9-delta-tetrahydrocannabinol (THC) in individuals with euthymic bipolar disorder (BD), and to begin probing the mechanisms that may underlie its effects in this illness. This study is expected to contribute to a better characterization of specific effects of THC in individuals with BD compared to healthy controls (HC).
Interventions
- DRUG Placebo
- DRUG 4 mg Delta-9-THC
- DRUG 2 mg Delta-9-THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2017-09-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03206463
The ClinicalTrials.gov registry entry for NCT03206463 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03206463 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03206463 about?
NCT03206463 is a clinical study titled "Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder". The overarching goal of this study is to characterize the acute cognitive and psychophysiological effects of the main psychoactive constituent of cannabis, 9-delta-tetrahydrocannabinol (THC) in individuals with euthymic bipolar disorder (BD), and to begin probing the mechanisms that may underlie its...
What is the current status of trial NCT03206463?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-08-01. Estimated completion is 2017-09-29.
What interventions are being tested in trial NCT03206463?
The interventions under investigation include: Placebo (DRUG), 4 mg Delta-9-THC (DRUG), 2 mg Delta-9-THC (DRUG).
Who is sponsoring clinical trial NCT03206463?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.